Last reviewed · How we verify
NCT07231952
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Phase 2 trial testing Pirtobrutinib in Waldenstrom Macroglobulinemia in 40 participants. Currently enrolling.
11 April 2028
Quick facts
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 11 November 2025 |
| Primary completion | 11 April 2028 |
| Estimated completion | 11 April 2028 |
| Sites | 8 locations across United States |
Drugs / interventions tested
- Pirtobrutinib — full drug profile →
- Venetoclax (venetoclax) — full drug profile →
- Rituximab — full drug profile →
Conditions studied
- Waldenstrom Macroglobulinemia — all drugs for Waldenstrom Macroglobulinemia →
- Lymphoplasmacytic Lymphoma — all drugs for Lymphoplasmacytic Lymphoma →
Sponsor
Memorial Sloan Kettering Cancer Center — full company profile →
Who can join
18 and older, any sex, with Waldenstrom Macroglobulinemia or Lymphoplasmacytic Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to find out if the combination of pirtobrutinib, venetoclax, and rituximab is an effective treatment for participants with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07231952
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pirtobrutinib
Trials testing the same drug.
- NCT07525817 — A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma · not yet recruiting
- NCT07428707 — Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib · EARLY_PHASE1 · recruiting
- NCT07207785 — PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma · Phase 2 · not yet recruiting
- NCT07342478 — ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL · Phase 3 · not yet recruiting
- NCT07255963 — Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL · Phase 2 · recruiting
Other recruiting trials for Waldenstrom Macroglobulinemia
Currently open trials in the same condition.
- NCT06860880 — Combating Cancer-Related Fatigue: A Personalized Supportive Care Program · NA · recruiting
- NCT06561347 — Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM · Phase 2 · recruiting
- NCT06510491 — Epcoritamab in Previously Treated WM · Phase 2 · recruiting
- NCT06151730 — Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies U · recruiting
- NCT05734495 — Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia · Phase 2 · recruiting
Other Memorial Sloan Kettering Cancer Center trials
Trials by the same sponsor.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
- NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
- NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
- NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07231952 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
- Last refreshed: 17 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07231952.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing